Lindsay A. Renfro, PhD

Professor of Research Population and Public Health Sciences

Children’s Oncology Group Associate Group Statistician

Image of Lindsay A. Renfro, PhD
Is this your profile? Click to edit

Overview

Dr. Lindsay Renfro is a Professor of Research at the University of Southern California and the Associate Group Statistician for Children’s Oncology Group (COG). COG is the pediatric cooperative group member of the NIH/NCI’s National Clinical Trials Network and the world’s largest organization dedicated exclusively to pediatric cancer research. Within COG, Dr. Renfro is also Lead Statistician for the Renal Tumors and Hodgkin Lymphoma Committees, where she leads the design and analysis of therapeutic and biology-driven clinical trials and related projects in pediatric, young adult, and adult cancer. Her expertise and methodological interests include novel trial designs (e.g., adaptive, Bayesian, biomarker-driven, and master protocols); evaluation, validation, and use of surrogate endpoints in clinical trials; and construction, validation, and implementation of disease-specific prognostic calculators for clinical use and decision-making. Outside of USC and COG, Dr. Renfro serves on the Head and Neck Steering Committee and the Adult Late Phase Emphasis Central IRB for NCI. Dr. Renfro also enjoys teaching statistics to non-statisticians, mentoring students, traveling, and enjoying the mountains and beaches of Southern California with her son.

Awards

  • Texas Woman’s University: Hallmark Alumni Award, 2018
  • Mayo Clinic: KL2 Mentored Career Development Award, 2015
     – 2018
  • ENAR / International Biometric Society: Distinguished Student Paper Award, 2011
  • Baylor University: Dean’s Stipend Enhancement Award, 2006
     – 2011
  • National Science Foundation, National Center for Education Statistics: Fellow, National Summer Data Policy Institute, 2010
  • Association for Institutional Research, National Center for Education Statistics: AIR/NCES Graduate Fellowship, 2008
     – 2010
  • Association for Institutional Research: Best Paper Award, 2007
  • Kappa Mu Epsilon National Mathematics Honor Society: Best Paper Award, 2005
  • Texas Woman’s University: Chancellor’s Research Scholar, 2005
  • Texas Woman’s University: Harlan Miller Award and Memorial Scholarship, 2004
     – 2005
  • Texas Instruments: Women in Engineering Award and Scholarship, 2003
     – 2005

Education and Training

  • Texas Woman's University — B.S. — 05/2005 — Mathematics
  • Rice University — Ph.D. Student — 05/2006 — Statistics
  • Baylor University — M.S. — 12/2007 — Statistics
  • Baylor University — Ph.D. — 03/2011 — Statistics

Research Funding

  • Children's Oncology Group Statistics and Data Center
    NIH · U10CA180899 · Apr 15, 2014 – Feb 29, 2032 · Role: Co-Investigator

Research Keywords

  • clinical trials
  • adaptive design
  • Bayesian adaptive design
  • biomarker-driven trials
  • basket trials
  • umbrella trials
  • cancer clinical trials
  • pediatric cancer trials
  • Wilms tumor
  • Hodgkin lymphoma
  • cancers affecting adolescent and young adult (AYA) populations
  • surrogate endpoints
  • surrogate endpoint evaluation
  • clinical prediction modeling
  • clinical calculators
  • patient calculators
  • calculator construction and validation

Publications

  • Concordance Between Institutional and Central Pathology, Surgery, and Radiology Reviews on the Children’s Oncology Group AREN03B2 Renal Tumor Biology and Classification Study. Pediatr Blood Cancer. 2026 Aug 04.. View in PubMed
  • Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children’s Oncology Group Trials. Pediatr Blood Cancer. 2026 Jul 24.. View in PubMed
  • Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children’s Oncology Group (COG) AHOD1331 trial. Br J Haematol. 2026 Jul 08.. View in PubMed
  • Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial. J Nucl Med. 2026 Jun 18.. View in PubMed
  • Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes. J Biopharm Stat. 2026 Jun 11; 1.. View in PubMed
  • Integrated Molecular, Genomic, and Clinical Characterization of Pediatric and Adolescent Translocation Renal Cell Carcinoma: A Report from the Children’s Oncology Group. Biomedicines. 2026 Apr 22; 14(5).. View in PubMed
  • Subsequent Neoplasm Risk After Modern Mediastinal Radiation Therapy for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial. Int J Radiat Oncol Biol Phys. 2026 07 15; 125(4):1121-1129.. View in PubMed
  • Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13; 10(1):183-191.. View in PubMed
  • Enhancing Radiation Therapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131. Int J Radiat Oncol Biol Phys. 2026 07 01; 125(3):737-742.. View in PubMed
  • An efficient single-arm Bayesian adaptive trial algorithm to evaluate de-intensified oncologic treatment. Trials. 2025 Dec 10; 27(1):34.. View in PubMed